{
  "type": "add_node",
  "timestamp": "2025-08-15T02:02:14",
  "processed": false,
  "inputs": {
    "source_article_id": "KQAL1U7PW",
    "status": "rejected",
    "reject_category": "asset",
    "reject_failure_cat": "not_macro"
  },
  "details": {
    "llm_topic_proposal_raw": {
      "motivation": "The article highlights Reviva Pharmaceuticals' lead drug candidate, brilaroxazine, which is pivotal for its future revenue potential and regulatory strategy, warranting a dedicated node for investment analysis.",
      "id": "brilaroxazine",
      "name": "Brilaroxazine",
      "type": "asset",
      "level": "main"
    },
    "topic_category": {
      "category": "asset",
      "motivation": "Drug candidate is a financial asset for Reviva Pharmaceuticals."
    },
    "relevance_gate": {
      "should_add": false,
      "reason": "Brilaroxazine is a clinical‑stage drug candidate, a product category, not a macro driver or tradable asset; it does not provide macro‑level market insight.",
      "confidence": 0.95,
      "failure_category": "not_macro"
    }
  },
  "id": "none"
}